Technical considerations for the performance of Nucleic acid Amplification Technology (NAT)

Biologicals

Volumn 31, Issue 3, 2003, Pages 153-159

  Chudy, Michael ^m   Hewlett, Indira ^a   Saldanha, John ^b   Bianco, Celso ^c   Conrad, Andrew J ^d   Gierman, Todd ^e   Heldebrant, Charles ^f   Rautmann, Guy G ^g   Roth, W Kurt ^h   Stramer, Susan ⁱ   Weimer, Thomas ^j   Whitaker, Barbee ^k   Zerlauth, Gerold ^l  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c America's Blood Centers   (United States)

^d National Genetics Institute   (United States)

^e BAYER CORPORATION   (United States)

^f Grifols SA   (United States)

^g European Directorate for the Quality of Medicines   (France)

^h Institute Springe   (Germany)

ⁱ AMERICAN RED CROSS BLOOD SERVICES   (United States)

^j SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^k Plasma Protein Therapeutics Association   (United States)

^l BAXTER BIOSCIENCE   (Austria)

^m NONE

more..

Author keywords

Blood; NAT; Plasma; Viral testing minimum requirements

Indexed keywords

ACCURACY; ARTICLE; ASSAY; BLOOD; CONTROLLED STUDY; HUMAN; LABORATORY; MICROORGANISM DETECTION; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; PLASMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SERUM;

EID: 12444323020     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1045-1056(03)00020-4     Document Type: Article

References (0)